Почетна › Trostruko negativni rak dojke › Тенеси
Kliničke studije za Trostruko negativni rak dojke u državi Тенеси
31 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Тенеси.
Gradovi u državi Тенеси
Zvanični tekst studije (na engleskom)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05422794A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Tennessee Cancer Specialists ( Site 7001), Knoxville
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07503808Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 9. 11. 2026. · NCT07652242A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- West Cancer Center and Research Institute ( Site 0084), Germantown
- Baptist Cancer Center ( Site 0101), Memphis
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06393374A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06150664Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University of Tennessee, Knoxville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Study of XB010 in Subjects With Solid Tumors
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06545331A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Sarah Cannon Research Institute (SCRI), Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06908928Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Vanderbilt University Medical Center, Nashville
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04981119SMP-3124LP in Adults With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06526819Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- SCRI Oncology Partners /ID# 261568, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06799065The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 21. 9. 2026. · NCT05983432Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Nashville General, Nashville
Тражи се учесникОпсервациона студија
Узраст од 18 до 99 · Оба пола · Ажурирано 3. 9. 2026. · NCT07211178A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT04895709A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
- Vanderbilt University/Ingram Cancer Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 24. 6. 2026. · NCT05770531Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
- Vanderbilt-Ingram Cancer Center, Nashville
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT07555210Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Vanderbilt-Ingram Cancer Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 5. 2026. · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Sarah Cannon Research Institute, Chattanooga
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 4. 2026. · NCT04468061A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- West Cancer Centre, Germantown
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 1. 2026. · NCT06926920Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Vanderbilt University/Ingram Cancer Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2025. · NCT07016399Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.